Related Experiment Video
Updated: Feb 18, 2026
07:13
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
5.3K
Macitentan in daily clinical practice: A single centre, 1-year experience
S Cadenas-Menéndez1, P Álvarez-Vega1, J Martín-Moreiras2
1Pulmonology Service, Pulmonary Hypertension Unit, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain.
Pulmonology
|November 28, 2017
Summary
Macitentan, a dual endothelin-receptor antagonist, significantly improved functional class, 6-minute walk distance, and NT-proBNP levels in pulmonary arterial hypertension patients. The treatment demonstrated safety and efficacy in a real-world clinical setting.
Area of Science:
- Cardiology
- Pulmonology
- Pharmacology
Background:
- Pulmonary arterial hypertension (PAH) is a severe condition.
- Macitentan is an approved dual endothelin-receptor antagonist (ERA) for PAH treatment.
- Clinical trials have established its efficacy and safety for morbidity and mortality events.
Purpose of the Study:
- To evaluate the real-world utilization and outcomes of macitentan in a single clinical center.
- To assess macitentan's effectiveness in a diverse PAH patient population with various aetiologies and prior treatments.
Main Methods:
- Retrospective analysis of 13 patients with PAH treated with macitentan.
- Assessment of functional class (FC), 6-minute walk distance (6MWD), and NT-proBNP levels at 12 months.
- Evaluation of cardiac imaging parameters and clinical outcomes including hospitalizations, septostomy, transplant, or death.
Main Results:
- Significant improvement in functional class for 11 out of 13 patients.
- All patients demonstrated improved 6-minute walk distance.
- Reduced NT-proBNP plasma levels in 10 patients.
- Observed improvements in cardiac imaging parameters.
- No patients required hospitalization, septostomy, transplant, or experienced death during the study period.
Conclusions:
- Macitentan treatment showed significant clinical benefits in a real-world PAH patient cohort.
- The drug was well-tolerated and effective in improving functional capacity and relevant biomarkers.
- These findings support the use of macitentan in managing PAH in routine clinical practice.
Related Concept Videos
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
282
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
282
01:15Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
280
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
280
01:29Therapeutic Drug Monitoring: Affecting Factors
257
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
257
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
490
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
490
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
20
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
20